VAL-083 is a structurally unique, "first-in-class", small-molecule chemotherapeutic. Based on historical data and our own research, we believe that VAL-083 has the potential to offer physicians and patients a new paradigm in the treatment of Glioblastoma Multiforme (GBM).
Recruiting
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE): More InformationActive, not recruiting
The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of
For Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma: More InformationActive, not recruiting
The purpose of this Phase 2, open-label, single-arm study is to determine the safety and the
For Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression: More InformationWithdrawn
This is an open label, multi-center, Phase 1/2 clinical trial in subjects with recurrent
A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer (REPROVe): More InformationThe purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and
For Patients With Recurrent Malignant Glioma: More InformationThis Policy for Requests for Expanded Access to Investigational Drugs describes the principles and procedures that Kintara Therapeutics, Inc. will follow when considering requests by licensed physicians for use of Kintara’s investigational drugs outside of clinical trials.
